Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-06-06
1999-09-07
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540145, A61K 31555, C07D48722
Patent
active
059487712
ABSTRACT:
A method to improve the contractile function of the heart in myocarditis and other forms of heart failure is disclosed. The method consists essentially of administering a tetrapyrrole or metallotetrapyrrole which inhibits or reduces the endogenous guanylyl cyclase activity in cardiac myocyte of the patient.
REFERENCES:
patent: 4829984 (1989-05-01), Gordon
patent: 4997639 (1991-03-01), Aizawa et al.
patent: 5214036 (1993-05-01), Beth et al.
patent: 5298018 (1994-03-01), Narisco, Jr. et al.
patent: 5422362 (1995-06-01), Vincent et al.
patent: 5447939 (1995-09-01), Glasky et al.
patent: 5451599 (1995-09-01), Graczyk et al.
Garthwaite, J. (1995) "Potent and Selective Inhibiton of Nitric quinoxalin-1-one" Molecular Pharmacology 48: 184-88.
Anderson, K.E. (1986) "Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans" Clin. Pharmacol. Ther. 39(5): 510-520.
Atanassova, et al. (1992) "Effects of Isosorbide-5-mononitrate and Isosorbide-2-mononitrat on the Contractile and Cyclie Nucleotides in Isoalted Heart Muscles of the Guinea-pig and Dog" J. Pharm. Pharmacol. 44(8): 663-666.
Balligand, et al. (1993) "Abnormal Contractile Funtion due to Induction of Nitric Oxide Synthesis in Rat Cardiac Myocytes Follows Exposure to Activated Macophage-conditioned Medium" Journal of Clinical Investigation 91(5): 2314-2319.
Balligand, et al. (1993) "Control of Cardiac Muscle Cell Function by an Endogenous Nitric Oxide Signaling System" Proc. Natl. Acad. Sci. 90(1): 347-51.
Berglund, et al. (1988) "Sn-Protoporphyrin Lowers Serum Bilirubin Levels, Decreases Biliary Bilirubin Output, Enhances Biliary Heme Excretion and Potently Inhibits Hepatic Heme Oxygenase Activity in Normal Human Subjects" Hepatology 8(3): 625-631.
Braughler, J.M. et al. (1979) "Purification of soluble guanylate cyclase from rat liver" Proc. Natl. Acad. Sci. (76) 1: 219-222.
Chen, L. et al. (1992) "Electron spin resonance determination and superoxide dismutase activity in polymorphonuclear leukocytes in congestive heart failure" Canadian J. Cardiol. 8(7): 756-60.
Ewing, J.F., (1994) "Induction of Heart Heme Oxygenase-1 (HSP32) by Hyperthemia: Possible Role in Stress-Mediated Elevation of Cyclic 3', 5'-Guanosine Monophosphate".
Gennaro, A.R., Ed., (1985) "Remington's Pharmaceutical Sciences", 17th ed., Mack Publishing Company, Easton, PA, p. 1418.
Greene, T.W., et al., 2nd Ed., (1981) Protective Groups in Organic Synthesis, John Wile and Sons.
Gross, E. et al. (1981) The Peptides-Analysis, Synthesis, Biology, Academic Press.
Habib, F., (1994) "Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism" Lancet 344(8919): 371-3.
Honeybourne, et al. (1979) "The Interaction of Mitochondrial Ferrochelatase with a range of Porphyrin Substrates" FEBS Letters 98(1): 207-210.
Ignarro, L.J., (1994) "Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins" Advances in Pharmacology 26:35-65.
Jones M.S. (1969) "The Structural Organization of Haem Synthesis in Rat Liver Mitochondria" The Biochemical Journal 113: 507-514.
Kappas, et al., (1988) "Sn-Protoporphyrin Use in the Management of Hyperbilirubinemia in Term Newborns With Direct Coombs-Positive ABO Incompatibility" Pediatrics 81(4): 485-497.
Lincoln, et al., (1991) "Towards an Understanding of the Mechanism of Action of Cyclic AMP and Cyclic GMP in Smooth Muscle Relaxation" Blood Vessels, 28: 129-137.
O'Murchu, B. et al. (1994) "Increased Production of Nitric Oxide in Coronary Arteries during Congestive Heart Failure" J. Clin. Invest. 93(1): 165-171.
Roberts, D.C. et al. (1983) "Unusual Amino Acids in Peptid Synthesis" The Peptides-Analysis, Synthesis, Biology Volume 5: 342-429.
Rubaltelli, F.F., (1989) "Tin-Protoporphyrin in the Management of Children with Crigler-Najjar Disease" Pediatrics 84(4): 729-31.
Schmidt, H.W. et al., (1991) "Purification on a soluble isoform of guanylyl cyclase-activating-factor synthase" Proc. Natl. Acad. Sci. USA, 88: 365-369.
Schmidt, H.W. et al., (1992) "NO, CO and OH Endogenous soluble guanylyl cyclase-activating factors" FEBS 307(1): 102-07.
Singh, N., et al. (1995) "Oxidative stress and heart failure" Mol. Cell. Biochem. 147: 77-81.
Slungaard, A.J. (1991) "Bromide-dependent Toxicity of Eosinophil Peroxidase for Endothelim and Isolated Working Rat Hearts: A model for Eosinophilic Endocaritis" Exper. Med. 173(1): 117-26.
Winlaw, D.A. et al. (1994) "Increased nitric oxide production in heart failure" Lancet 344 (8919): 373-4.
Wong, et al. (1992) "Receptor Gyanylyl Cyclases" J. Clin. Invest. 90(2): 299-305.
Yang, X. et al. (1994) "Induction of Myocardial Nitric Oxide Synthese by Cardiac Allograft Rejection" J. Clin. Invest. 94(2): 713-21.
Torfgard et al. "Mechanism of action of nitrates" Index Medicus 95:178406, 1995.
Fitton et al. "Isradipine. A review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in cardiovascualr disease" Index Medicus 90:360912, 1990.
Colucci et al. "Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure" Index Medicus 81:229559, 1981.
Stephenson et al. "Acetylcholinesterase inhibitors . . . , " CA 112:229664, 1990.
Silveira et al. "Vascular effects of acetylcholinesterase inhibitors . . . , " CA 117:103972, 1992.
Brunner et al. "Novel guanylyl cyclase inhibitor . .. " CA 124:313545, 1996.
Luo et al. "Mettalloporphyrins inhibit oxide . . . " Eur. J. Pharm. mol. pharm. v.267, pp. 263-267, 1994.
Sulakhe et al. Biochem. J. v.157, pp. 705-712, 1976.
Wyngaarden et al. "Cecil textbook of medicine" Sander Co. pp. 107-108, 243-244, 1983.
Chang Ceila
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Method for treating heart failure using tetrapyrroles and metall does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating heart failure using tetrapyrroles and metall, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating heart failure using tetrapyrroles and metall will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804634